Authors: Peer Tfelt-Hansen
Source: The Lancet Neurology, Volume 14, No. 1, p31–32, January 2015
In The Lancet Neurology, David Dodick and colleagues1 report an important study of treatment in migraine prophylaxis: parenteral administration of LY2951742, a monoclonal antibody to calcitonin gene-related peptide (CGRP). Mean decrease from baseline in migraine days in 4 weeks was higher in patients given LY2951742 (4·2) than in those given placebo (3·0; p=0·003).1 Results of other trials that use antibodies against CGRP will probably be published soon.2